Multidrug Resistant Bacteria Market - Industry Trends and Forecast to 2029

In recent years, the multidrug resistant bacteria market is anticipated to grow rapidly during the forecast period. As per the Centers for Disease Control and Prevention (CDC), around 1.7 million illnesses and 99,000 related fatalities occur each year in American hospitals, according to the CDC. Additionally, the infection disease rate is expected to develop due to an increase in demand for point-of-care testing. In the future years, these factors are projected to influence the growth of the worldwide multidrug resistant bacteria market.

Some of the major players operating in the
multidrug resistant bacteria market are:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Merck & Co., Inc. (US)
• AbbVie Inc. (US)

Get More Info : https://www.databridgemarketresearch.com/reports/global-multidrug-resistant-bacteria-market
Global Multidrug Resistant Bacteria Market, By Diseases (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital Acquired Bacterial Pneumonia, Acquired Bacterial Pneumonia, Others), Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae, Others), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2029

Data Bridge Market Research analyses that the multidrug resistant bacteria market was valued at USD 10.359 billion in 2021 and is expected to reach USD 16.02 billion by 2029, registering a CAGR of 5.60% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Every now and then, a new strain of bacteria is discovered that has developed a high level of resistance to antibiotics. Multidrug resistant bacteria, also known as superbugs, are microorganisms that have developed resistance to multiple drugs or antibiotics used to treat infectious diseases.

More Links:

https://dbmr232343.blogspot.com/2023/07/medical-imaging-market-trends-drivers.html

https://dbmr232343.blogspot.com/2023/07/middle-east-and-africa-healthcare.html

https://dbmr232343.blogspot.com/2023/07/emerging-trends-and-opportunities-in.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.